Cheray Lynch Sieminski

Overview

Cheray Lynch Sieminski provides forensic analysis and regulatory advisory services to healthcare and life sciences companies and their legal counsel. She develops innovative, efficient solutions and analytical tools to examine and quantify business and legal issues in the context of commercial litigation, government investigations, and other regulatory-driven initiatives. She has substantial experience in the execution of complex, high-profile, data-intensive projects with multidisciplinary teams.

Investigations and disputes in health benefit contracting with private and government-sponsored health programs

Investigations and disputes related to pharmaceutical sales and marketing practices

Investigations related to financial reporting in response to alleged violations of the Foreign Corrupt Practices Act and other anti-bribery laws and regulatory guidelines and standards

Ms. Sieminski has assimilated and analyzed massive datasets from historical, disparate, and relational company transaction systems, as well as information from publicly available resources. Her industry knowledge has been leveraged on numerous litigation, investigation, and regulatory matters. She has worked with corporate and external counsel to develop and respond to data requests, develop effective affirmative and defensive analysis, articulate technical issues to other parties, and prepare for settlement negotiations or trial.

BRG experts have assisted a number of pharmaceutical manufacturers and their outside counsel with disputes related to allegedly fraudulent and inflated average wholesale prices for drugs in the so-called “AWP matters.”

Areas of Expertise

Sign up for our Newsletter

Enter email to get started

X Code

Berkeley Research Group (BRG) is a different kind of consulting firm: one that makes intelligence work by combining data analysis with extensive sector experience, creative perspectives with deep business acumen, and big-picture thinking with executable direction to help you stay ahead of what’s next.